Dopamine hydrochloride, first approved in the USA on February 25, 1974, is a medication developed and marketed by Hospira. It is indicated for the treatment of heart failure and shock. Dopamine hydrochloride works as a dopamine agonist, which means that it binds to and activates dopamine receptors in the body. This results in increased cardiac output and improved blood flow to vital organs. The chemical name for dopamine hydrochloride is 3,4-dihydroxyphenethylamine hydrochloride. As the hydrochloride salt form of dopamine, it is more stable and soluble in water, making it suitable for intravenous administration in clinical settings. Click on the image below to begin the exploration journey of Dopamine through the Synapse database!
You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!